Constructing rendering of a brand new, state-of-the-art science and innovation heart at Amgen’s world headquarters in Thousand Oaks, California.
Courtesy: Amgen
Amgen on Tuesday mentioned it would spend greater than $600 million to construct a brand new analysis and improvement facility at its headquarters in Thousand Oaks, California, the most recent in a string of new U.S. investments by the pharmaceutical trade.
Drugmakers have been scrambling to spice up their presence within the U.S. as President Donald Trump threatens to clamp down on the trade with tariffs on prescription drugs imported into the nation. Trump has mentioned these levies will incentivize corporations to re-shore manufacturing at a time when home drug manufacturing has shrunk dramatically over the previous decade.
In a launch, Amgen mentioned development of the power will start within the third quarter of this yr and can create lots of of U.S. jobs.
Notably, the power will not be a producing plant, however it would enable researchers, engineers and scientists to collaborate on discovering next-generation medication for sufferers with “probably the most critical illnesses,” in keeping with the corporate. Amgen mentioned the constructing options “superior automation and digital capabilities,” which can give scientists the mandatory instruments for that analysis and improvement.
“At Amgen, we’re persevering with to put money into the way forward for American science and innovation,” CEO Bob Bradway mentioned within the launch. “The middle will empower our scientists with the instruments and collaborative surroundings they should form the subsequent period of scientific discovery and advance medicines that enhance human well being.”
Amgen mentioned that for the reason that passage of the Tax Cuts and Jobs Act of 2017, it has invested virtually $5 billion in direct U.S. capital expenditures. In April, the corporate introduced a $900 million growth of its Ohio biotech manufacturing facility. In December, the drugmaker introduced it will spend $1 billion to construct a second drug substance plant in Holly Springs, North Carolina.
These investments come after the U.S. Meals and Drug Administration in August launched a program that goals to make it simpler for corporations to arrange new drug manufacturing vegetation within the U.S. The White Home estimates it may possibly presently take 5 to 10 years to construct new manufacturing capability for prescription drugs, which it beforehand known as “unacceptable from a national-security standpoint.”
